Despite the fact that PSMA PET imaging has gradually been incorporated in many countries in the staging and management of prostate cancer, its access is currently restricted to clinical trials in the single‐payer healthcare system in Ontario Canada. Here, FOLH1 is linked to prostate carcinoma.